Select therapeutic use:
Indications for FEMTRACE:
Moderate to severe vasomotor symptoms of menopause.
Start at lowest effective dose. 1 tablet daily.
Breast- or estrogen-dependent cancer. Thromboembolic disorders. Undiagnosed abnormal genital bleeding. Hepatic dysfunction or disease. Pregnancy (Cat.X).
Patients with an intact uterus should always receive a progestin to avoid endometrial hyperplasia. Reevaluate periodically. Conditions aggravated by fluid retention. Hypertriglyceridemia. Do initial complete physical exam and repeat annually (include BP, mammogram, and PAP smear). Discontinue if jaundice occurs. Nursing mothers.
May be affected by CYP3A4 inducers or inhibitors.
See literature. Headache, mastodynia, vaginal bleeding/discharge, GI upset, visual abnormalities; cardiovascular or gallbladder effects, fluid retention, others.